PRODUCT INFORMATION



Paliperidone-d₄

Item No. 28484

CAS Registry No.: 1020719-55-4

Formal Name: 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-

1-piperidinyl]ethyl-1,1,2,2-d₄]-6,7,8,9tetrahydro-9-hydroxy-2-methyl-4H-

pyrido[1,2-a]pyrimidin-4-one

9-hydroxy Risperidone-d₄ Synonym:

MF: $\mathrm{C}_{23}\mathrm{H}_{23}\mathrm{D}_4\mathrm{FN}_4\mathrm{O}_3$

FW: 430.5


Chemical Purity: ≥95% (Paliperidone)

Deuterium

 \geq 99% deuterated forms (d₁-d₄); \leq 1% d₀ Incorporation:

Supplied as: A solid -20°C Storage: ≥4 years Stability:

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Paliperidone-d₁ is intended for use as an internal standard for the quantification of paliperidone (Item No. 15556) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Paliperidone- d_A is supplied as a solid. A stock solution may be made by dissolving the paliperidone- d_A in the solvent of choice, which should be purged with an inert gas. Paliperidone-d₄ is slightly soluble in chloroform, DMSO, and methanol.

Description

Paliperidone is an atypical antipsychotic. 1 It is an inverse agonist of dopamine D₂ and D₃ receptors $(IC_{50}s = 1 \text{ and } 0.9 \text{ nM}, \text{ respectively})$, as well as an antagonist at these receptors ($K_is^2 = 0.4 \text{ and } 0.1 \text{ nM}$, respectively).² Paliperidone also binds to α_1 - and α_2 -adrenergic receptors, histamine H_1 receptors, and the serotonin (5-HT) receptor subtypes 5-HT_{1A}, 5-HT_{2A}, and 5-HT_{2C} (K_ds = 10.1, 80, 3.4, 480, 19, 1.21, and 48 nM, respectively).³ It improves spatial working memory in a T-maze alternation task in a maternal immune activation mouse model of schizophrenia when administered at a dose of 0.05 mg/kg per day.¹ Paliperidone is also an active metabolite of the atypical antipsychotic risperidone (Item No. 13629).³ Formulations containing paliperidone have been used in the treatment of schizophrenia and schizoaffective disorder.

References

- 1. MacDowell, K.S., Munarriz-Cuezva, E., Caso, J.R., et al. Neuropharmacology 116, 196-207 (2017).
- 2. Burstein, E.S., Ma, J., Wong, S., et al. J. Pharmacol. Exp. Ther. 315(3), 1278-1287 (2005).
- 3. Richelson, E. and Souder, T. Life Sci. 68(1), 29-39 (2000).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 12/15/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM